Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 1

Status

Completed 3Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 4Gastrointestinal 2

Conditions

Colorectal Neoplasms 86Ovarian Neoplasms 33Breast Neoplasms 29Carcinoma, Non-Small-Cell Lung 28Colonic Neoplasms 23Rectal Neoplasms 21Fallopian Tube Neoplasms 17Neoplasms 16Neoplasm Metastasis 13Carcinoma, Hepatocellular 13Glioblastoma 11Lung Neoplasms 10Brain Neoplasms 8Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Intestinal Neoplasms 5Gastrointestinal Neoplasms 5Digestive System Neoplasms 5Brenner Tumor 5Recurrence 4Peritoneal Neoplasms 4Glioma 4Carcinoma, Ovarian Epithelial 4Adenocarcinoma of Lung 4Rectal Diseases 3Non-Squamous Non-Small Cell Lung Cancer 3Liver Neoplasms 3Intestinal Diseases 3Gastrointestinal Diseases 3

Interventions

pembrolizumab 95Cisplatin 35Paclitaxel 27Carboplatin 27Docetaxel 17lenvatinib 15Fluorouracil 14Saline Solution 13Capecitabine 12Pemetrexed 10Gemcitabine 10Oxaliplatin 9Cetuximab 7Albumin-Bound Paclitaxel 7olaparib 6epacadostat 6Bevacizumab 6130-nm albumin-bound paclitaxel 6Leucovorin 5enzalutamide 4Etoposide 4trifluridine tipiracil drug combination 3regorafenib 3belzutifan 3Prednisone 3Irinotecan 3Glucose 3Dexamethasone 3liposomal doxorubicin 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Parkinson Disease 4, Autosomal Dominant Lewy Body × Bevacizumab × Clear all
NCT05239741 2026-05-22

MK-3475-C66

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
100 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT07216703 2026-05-22

TroFuse-036

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,023 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03740165 2026-05-04

KEYLYNK-001

Merck Sharp & Dohme LLC

Phase 3 Completed
1,367 enrolled 29 charts
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

Merck Sharp & Dohme LLC

Phase 3 Completed
617 enrolled 29 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT02563002 2024-10-03

KEYNOTE-177

Merck Sharp & Dohme LLC

Phase 3 Completed
307 enrolled 16 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡